REDWOOD CITY, CA – May 10, 2012 – Incline Therapeutics, Inc., a hospital-focused specialty pharmaceutical company, announced today the appointment of John Tucker as Senior Vice President and Chief Commercial Officer. Mr. Tucker has 20 years of experience building and leading pharmaceutical commercial organizations with a significant focus in the hospital market. He will serve as a member of Incline’s senior leadership team and have broad responsibility for sales, marketing, and other commercial operations. Mr. Tucker joins Incline
REDWOOD CITY, CA – March 1, 2012 – Incline Therapeutics, Inc., a hospital-focused specialty pharmaceutical company, announced today that Alan Levy, PhD, Chief Executive Officer, and David Socks, President and Chief Operating Officer, will present at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 10:00a.m. Eastern Time at the Boston Marriott Copley Place. About Incline Therapeutics, Inc. Incline Therapeutics is a hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system),
REDWOOD CITY, CA – February 13, 2012 – Incline Therapeutics, Inc., a hospital-focused specialty pharmaceutical company, announced today that Alan Levy, PhD, Chief Executive Officer, and David Socks, President and Chief Operating Officer, will present at the Leerink Swann Global Healthcare Conference on Wednesday, February 15, 2012 at 11:00a.m. Eastern Time at the Waldorf-Astoria Hotel in New York City. About Incline Therapeutics, Inc. Incline Therapeutics is a hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system), a
REDWOOD CITY, Calif., June 21, 2010 /PRNewswire/ -- Incline Therapeutics, Inc., a privately-held, hospital-focused specialty pharmaceutical company, announced today that it has entered into an agreement to acquire the rights to IONSYS™ (fentanyl iontophoretic transdermal system) from ALZA Corporation and completed a $43 million Series A financing. IONSYS™ Acquisition Under the terms of the agreement, Incline will receive an exclusive, worldwide license to IONSYS and will acquire certain other assets related to IONSYS. IONSYS™ (fentanyl iontophoretic transdermal system) is an investigational product candidate
